A combination of PD-1 antagonist and eribulin for treating cancer
- 专利权人:
- 머크 샤프 앤드 돔 코포레이션;머크 샤프 앤드 돔 코포레이션;에자이 알앤드디 매니지먼트 가부시키가이샤
- 发明人:
- 마츠이, 준지,악탄, 구르셀,카란차, 바실리키,위안, 루이롱,후나하시, 야스히로,베락, 에르한
- 申请号：
- KR1020177027617
- 公开号：
- KR1020170122810A
- 申请日:
- 2016.03.03
- 申请国别(地区):
- KR
- 年份:
- 2017
- 代理人:
- 摘要：
- This disclosure describes the use of combination therapy comprising a programmed death receptor (PD-1) antagonist and eribulin or a pharmaceutically acceptable salt thereof, and combination therapy for the treatment of cancer.본 개시내용은 프로그램화된 사멸 1 수용체 (PD-1)의 길항제 및 에리불린 또는 그의 제약상 허용되는 염을 포함하는 조합 요법, 및 암의 치료를 위한 조합 요법의 용도를 기재한다.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER
- COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF PROGRAMMED DEATH RECEPTOR (PD-1) ANTIBODIES AND A CXCR2 ANTAGONIST
- Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
- USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OF PREVENTION OF TOLL-LIKE RECEPTOR-4-ASSOCIATED DISORDERS
- Use of Toll-like receptor-9 agonists, Toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of Toll-like receptor-4-associated disorders
